Anika Therapeutics (ANIK) Price to Earnings (2010 - 2026)

Anika Therapeutics (ANIK) has reported Price to Earnings for 17 consecutive years, with 59.69 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to Earnings rose 256.1% year-over-year to 59.69 in Q2 2026; TTM through Jun 2026 was 92.05, a 3641.38% decrease from a year earlier, with the FY2025 full-year figure at 14.52, down 253.01% from the prior year.
• Price to Earnings was 59.69 for Q2 2026 at Anika Therapeutics, up from 38.31 in the prior quarter.
• Over five years, Price to Earnings peaked at 67.48 in Q4 2025 and troughed at 4271.27 in Q2 2024.
• A 5-year average of 272.8 and a median of 41.37 in 2023 frame the typical range for Price to Earnings.
• Across the five-year window, Price to Earnings slumped 2974.55% in 2024 and jumped 759.16% in 2025, its largest moves.
• Over 5 years, Price to Earnings stood at 42.99 in 2022, then tumbled by 52.25% to 20.53 in 2023, then slumped by 149.87% to 10.24 in 2024, then surged by 759.16% to 67.48 in 2025, then fell by 11.54% to 59.69 in 2026.
• The last three Price to Earnings figures came in at 59.69 (Q2 2026), 38.31 (Q1 2026), and 67.48 (Q4 2025), per Business Quant data.